Atypical CML (aCML) is a rare myelodysplastic/myeloproliferative neoplasm (MDS/MPN) characterized by neutrophilia with left-shift maturation and dysgranulopoietic features. Diagnosis also requires the exclusion of BCR-ABL1, PDGFRA and PDFRB rearrangements.
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The prognosis of aCML is poor with survival times of generally o30 months: patients may undergo transformation to AML or succumb to the effects of BM failure. 2 To date, allo-SCT in the chronic phase of the disease has been the only option to improve OS. 3 No specific, recurrent cytogenetic or molecular abnormalities have been described in aCML until the recent characterization of mutations within the genes encoding the G-CSF receptor (CSF3R) and SET binding protein 1 (SETBP1) in a significant proportion of patients with aCML and chronic neutrophilic leukaemia (CNL). 4, 5 Whereas the functional significance of SETBP1 mutations in aCML and CNL are not yet fully understood, the characterization of CSF3R mutations has revealed a possibility for targeted therapeutic intervention with tyrosine kinase inhibitors. Approximately 50-60% of CNL and aCML patients harbour an acquired CSF3R mutation that can be either membrane proximal or in the cytoplasmic tail of the receptor. These two classes of mutations exhibit different downstream signalling patterns: membrane proximal mutations activate the JAK/STAT pathway and are therefore potentially amenable to inhibition with JAK inhibitors such as ruxolitinib, whereas truncation mutations predominantly signal through SRC family kinases and therefore may be targeted by SRC inhibitors such as dasatinib. The most prevalent CSF3R mutation in aCML and CNL is the membrane proximal T618I. 4, 6 In addition to this potential for targeted therapy, identification of aCML-specific CSF3R mutations affords the opportunity for evaluation of these mutations as disease-specific markers of residual disease in those patients undergoing allo-SCT. Mutations of SETBP1 and CSF3R exons 14 and 17 were sought by Sanger sequencing in a retrospective series of eight patients with aCML, CNL or atypical MPN. The clinical courses of two aCML patients are described, both of whom possessed a heterozygous CSF3R p. Thr618Ile (T618I) mutation (c.15482C>T, reference sequence NG_016270.1).
A 60-year-old woman (Patient #1) presented in 2002 with what appeared to be morphologically CML but had a normal karyotype with no evidence of BCR-ABL1 by fluorescence in situ hybridization (FISH) or reverse transcription-PCR. She had no haematological response to 1 month of imatinib and commenced hydroxyurea. The pre-transplant work-up revealed worsening constitutional symptoms and adenopathy. Retrospectively, a CSF3R T618I mutation was detected 3 months pre-transplant (Figure 1a,  upper) . A reduced-intensity conditioning, sibling donor (CSF3R wild type) allo-SCT was performed. The initial post-allo-SCT course was unremarkable; however by day 72, whole blood donor chimerism was only 20% with the T618I mutation retrospectively still evident (Figure 1a, centre) . Full donor chimerism was not achieved and she relapsed 9 months post allo-SCT with increasing BM myeloblasts. Two doses of DLI and a subsequent course of daunorubicin, cytarabine, thioguanine (3+10) did not improve the chimerism status; the marrow remained hypoplastic with 10-15% blasts and continued evidence of the CSF3R T618I (Figure 1a,  lower) . The patient became red cell and platelet transfusion dependent, deteriorated and died 17 months post allo-SCT. No constitutional material was available from Patient #1 to demonstrate the somatic nature of the CSF3R T618I mutation.
A 48-year-old man (Patient #2) presented with an elevated white cell count and a hypercellular BM consistent with aCML. The patient had a normal karyotype, no evidence of BCR-ABL1, PDGFRA or PDGFRB rearrangements by FISH, with molecular studies demonstrating the absence of the JAK2 V617F and BCR-ABL1 transcripts but the presence of the CSF3R T618I mutation (Figure 1b, upper) . He commenced treatment with hydroxyurea and 6 weeks before allo-SCT the CSF3R T618I clone remained evident but at a reduced level (Figure 1b, centre) . He underwent a myeloablative allo-SCT with a sibling donor (CSF3R wild type). At day 30 post allo-SCT, he developed skin GvHD. The T618I mutation was not detected by sequencing on day 46 in whole peripheral blood (Figure 1b, lower) . He remains well on a tapering steroid dose with improving GvHD.
In other forms of MPN, allele-specific monitoring of diseaseassociated mutations, such as the JAK2 V617F and those within MPL exon 10 at defined time points, has been shown to be of value in predicting response to allo-SCT and may also aid in directing adoptive immunotherapy in those patients who relapse. [7] [8] [9] [10] Such approaches would improve the detection sensitivity above that of Sanger sequencing and potentially allow quantitation of mutation level. Both persistence and eradication of the CSF3R T618I described above, correlating with the clinical course in both patients, indicate that serial monitoring of CSF3R mutations in aCML patients undergoing allo-SCT is a useful adjunct in the assessment of transplant efficacy.
